Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy

J Allergy Clin Immunol. 2018 Mar;141(3):1002-1008. doi: 10.1016/j.jaci.2017.07.036. Epub 2017 Sep 1.

Abstract

Background: Birch pollen-related apple allergy is among the most prevalent food allergies in adolescent/adult subjects and mainly results from sensitization to the major birch pollen allergen Bet v 1 and subsequent cross-reaction with the apple protein Mal d 1. However, specific immunotherapy with birch pollen has inconsistent effects on apple allergy.

Objective: We sought to compare the safety and efficacy of sublingual immunotherapy (SLIT) with 2 formulations containing either rMal d 1 or rBet v 1 on birch pollen-related apple allergy.

Methods: Sixty participants with birch pollen-related apple allergy were randomized to daily sublingual application of placebo (n = 20) or 25 μg of rMal d 1 (n = 20) or rBet v 1 (n = 20) for 16 weeks. Adverse events were regularly recorded. Sublingual challenges with standardized doses of rMal d 1, skin prick tests with recombinant allergens, and measurements of allergen-specific IgE and IgG4 antibodies were performed before and after treatment.

Results: Both formulations caused comparable, mainly local adverse events. No systemic reactions occurred. Compared with the placebo and rBet v 1-treated groups, SLIT with rMal d 1 reduced rMal d 1-induced oral symptoms (P = .001 and P = .038) accompanied by longitudinally reduced rMal d 1-specific cutaneous reactions (P = .022) and enhanced IgG4/IgE ratios (P = .012). SLIT with rBet v 1 neither improved the clinical reactivity to rMal d 1 nor enhanced rMal d 1-specific IgG4/IgE ratios. Participants receiving placebo showed no allergen-specific changes.

Conclusion: Sublingual treatment with a recombinant food allergen was safe and clinically effective, as determined by using standardized challenges. We present a promising approach for the effective treatment of birch pollen-related apple allergy.

Keywords: Bet v 1; Food allergy; IgE; Mal d 1; allergen-specific immunotherapy; birch pollen allergy; birch pollen–related food allergy; recombinant allergens.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Sublingual
  • Adolescent
  • Adult
  • Aged
  • Antigens, Plant / administration & dosage*
  • Antigens, Plant / immunology
  • Female
  • Food Hypersensitivity / immunology
  • Food Hypersensitivity / therapy*
  • Humans
  • Immunoglobulin E / immunology
  • Male
  • Middle Aged
  • Plant Proteins / administration & dosage*
  • Plant Proteins / immunology
  • Rhinitis, Allergic, Seasonal / immunology
  • Rhinitis, Allergic, Seasonal / therapy*
  • Skin Tests
  • Sublingual Immunotherapy*

Substances

  • Antigens, Plant
  • MALD1 protein, Malus domestica
  • Plant Proteins
  • Bet v 1 allergen, Betula
  • Immunoglobulin E